of the Board on Global Health, both of the Institute of Medicine. He also chairs the U.S. Delegation to the U.S.-Japan Cooperative Medical Science Program.

STANLEY M. LEMON, M.D., (vice-chair), is Dean of the School of Medicine at the University of Texas Medical Branch at Galveston. He received his undergraduate degree in biochemical sciences from Princeton University summa cum laude, and his M.D. with honor from the University of Rochester. He completed postgraduate training in internal medicine and infectious diseases at the University of North Carolina at Chapel Hill, and is board certified in both. From 1977 to 1983, he served with the U.S. Army Medical Research and Development Command, directing the Hepatitis Laboratory at the Walter Reed Army Institute of Research. He joined the faculty of the University of North Carolina School of Medicine in 1983, serving first as Chief of the Division of Infectious Diseases, and then Vice Chair for Research of the Department of Medicine. In 1997, Dr. Lemon moved to the University of Texas Medical Branch as Professor and Chair of the Department of Microbiology & Immunology. He was subsequently appointed Dean pro tem of the School of Medicine in 1999, and permanent Dean of Medicine in 2000. Dr. Lemon’s research interests relate to the molecular virology and pathogenesis of the positive-stranded RNA viruses responsible for hepatitis C and hepatitis A. He is particularly interested in the molecular mechanisms controlling cap-independent viral translation, and the replication of these RNA genomes. He has published over 180 papers, and numerous textbook chapters related to hepatitis and other viral infections, and has a longstanding interest in vaccine development. He has served previously as chair of the Anti-Infective Drugs Advisory Committee and the Vaccines and Related Biologics Advisory Committee of the U.S. Food and Drug Administration, and is past chair of the Steering Committee on Hepatitis and Poliomyelitis of the World Health Organization’s Programme on Vaccine Development. He presently serves as Chairman of the U.S. Hepatitis Panel of the U.S.-Japan Cooperative Medical Sciences Program, and chairs an Institute of Medicine study committee related to vaccines for the protection of the military against naturally occurring infectious disease threats.

STEVEN J. BRICKNER, Ph.D., is Research Advisor, Antibacterials Chemistry, at Pfizer Global Research and Development. He received his Ph.D. in organic chemistry from Cornell University and was a NIH Postdoctoral Research Fellow at the University of Wisconsin-Madison. Dr. Brickner is a medicinal chemist with nearly 20 years of research experience in the pharmaceutical industry, all focused on the discovery and development of novel antibacterial agents. He is an inventor/co-inventor on 21 U.S. patents, and has published numerous scientific papers, primarily within the area of the oxazolidinones. Prior to joining Pfizer in 1996, he led a team at Pharmacia and Upjohn that discovered



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement